Free Trial
NASDAQ:ZSQR

Coeptis Therapeutics Q2 2025 Earnings Results & Report

Coeptis Therapeutics logo
$5.16 -0.34 (-6.18%)
As of 04:00 PM Eastern

Coeptis Therapeutics reported Q2 2025 earnings on August 14, 2025. The company reported EPS of -$1.17, while revenue was $0.20 million.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes

Coeptis Therapeutics EPS Results

Actual EPS
-$1.17
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Coeptis Therapeutics Revenue Results

Actual Revenue
$0.20 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Coeptis Therapeutics Q2 2025 Earnings FAQ

Coeptis Therapeutics (NASDAQ:ZSQR) reported earnings of -$1.17 per share for Q2 2025. The report was announced on Thursday, August 14, 2025.

Coeptis Therapeutics reported revenue of $0.20 million for Q2 2025.

Coeptis Therapeutics Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Coeptis Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Coeptis Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coeptis Therapeutics and other key companies, straight to your email.

About Coeptis Therapeutics

Coeptis Therapeutics (NASDAQ:ZSQR) is a biotechnology company focused on developing cell therapy platforms and other treatments for cancer and autoimmune diseases. The company’s research is centered on approaches intended to improve the targeting, flexibility and potential effectiveness of immune-cell therapies.

Its principal platform, SNAP-CAR, is designed to support adaptable chimeric antigen receptor (CAR) cell therapies that can target different disease-associated antigens. Coeptis has also pursued related therapeutic programs through collaborations and licensing arrangements, including research involving natural killer (NK) cells and other immune-based treatment technologies.

Coeptis is based in the United States and has focused primarily on developing its pipeline through strategic partnerships and biotechnology collaborations. The company’s programs remain investigational and are subject to preclinical and clinical development requirements before any potential commercialization.

View Coeptis Therapeutics Profile